Defining Personalized Care Plans in Metastatic Castration-Resistant Prostate Cancer

Access Activity

Overview / Abstract:


Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 26,730 deaths annually. Median overall survival remains less than 2 years.


Medical oncologists, urologists, oncology advanced practitioners, oncology and urology nurses, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer.


Upon completion of this activity, participants should be able to:

1. Assess predictive and prognostic markers to refine personalized care plans for patients with metastatic CRPC
2. Evaluate sequential treatment strategies and combination therapies for patients with metastatic CRPC
3. Apply emerging data on novel therapeutic regimens in treatment selection for patients with metastatic CRPC


Dec 17, 2018


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Tanya Dorff, MDTanya Dorff, MD (Chairperson)
Associate Professor of Clinical Medicine
Keck School of Medicine of USC

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc. and Genzyme.

Keywords / Search Terms

i3 Health, CRPC, castration-resistant prostate cancer, prostate cancer, oncology, urology, CME, CE, webinar, free CE, free CME, online CE, online CME, Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.